Skip to main content

Advertisement

SpringerLink
Log in

It’s What’s Up Front That Counts—Part Two: Esophageal Crohn’s Disease Complicated by Recurrent Upper Gastrointestinal Bleeding

  • Multicenter Seminars: IBD (MUSE: IBD)
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Ramaswamy K, Jacobson K, Jevon G, Israel D. Esophageal Crohn disease in children: a clinical spectrum. J Pediatr Gastroenterol Nutr. 2003;36:454–458.

    Article  Google Scholar 

  2. Lenaerts C, Roy CC, Vaillancourt M, Weber AM, Morin CL, Seidman E. High incidence of upper gastrointestinal tract involvement in children with Crohn disease. Pediatrics. 1989;83:777–781.

    CAS  PubMed  Google Scholar 

  3. Mashako MN, Cezard JP, Navarro J, et al. Crohn’s disease lesions in the upper gastrointestinal tract: correlation between clinical, radiological, endoscopic, and histological features in adolescents and children. J Pediatr Gastroenterol Nutr. 1989;8:442–446.

    Article  CAS  Google Scholar 

  4. De Felice KM, Katzka DA, Raffals LE. Crohn’s disease of the esophagus: clinical features and treatment outcomes in the biologic era. Inflamm Bowel Dis. 2015;21:2106–2113.

    Article  Google Scholar 

  5. Wang W, Ni Y, Ke C, Cheng Q, Lu Q, Li X. Isolated Crohn’s disease of the esophagus with esophago-mediastinal fistula formation. World J Surg Oncol. 2012;10:208.

    Article  Google Scholar 

  6. Clarke BW, Cassara JE, Morgan DR. Crohn’s disease of the esophagus with esophagobronchial fistula formation: a case report and review of the literature. Gastrointest Endosc. 2010;71:207–209.

    Article  Google Scholar 

  7. Decker GA, Loftus EV, Pasha TM, Tremaine WJ, Sandborn WJ. Crohn’s disease of the esophagus: clinical features and outcomes. Inflamm Bowel Dis. 2001;7:113–119.

    Article  CAS  Google Scholar 

  8. Ammoury RF, Pfefferkorn MD. Significance of esophageal Crohn disease in children. J Pediatr Gastroenterol Nutr. 2011;52:291–294.

    Article  Google Scholar 

  9. Aun MV, Ribeiro MR, Costa Garcia CL, Agondi RC, Kalil J, Giavina-Bianchi P. Esophageal candidiasis—an adverse effect of inhaled corticosteroids therapy. J Asthma. 2009;46:399–401.

    Article  CAS  Google Scholar 

  10. Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol. 2003;98:2146–2148.

    Article  CAS  Google Scholar 

  11. Iskandar H, Greer JB, Krasinskas AM, et al. IBD live series-case 8: treatment options for refractory esophageal Crohn’s disease and hidradenitis suppurativa. Inflamm Bowel Dis. 2017;23:1667–1677.

    Article  Google Scholar 

  12. Zezos P, Kouklakis G, Oikonomou A, Pitiakoudis M, Simopoulos C. Esophageal Crohn’s disease treated ‘topically’ with swallowed aerosolized budesonide. Case Rep Med. 2010. https://doi.org/10.1155/2010/418769.

    Article  Google Scholar 

  13. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.

    Article  Google Scholar 

  14. D’Haens G, Rutgeerts P, Geboes K, Vantrappen G. The natural history of esophageal Crohn’s disease: three patterns of evolution. Gastrointest Endosc. 1994;40:296–300.

    Article  Google Scholar 

  15. Isaacs KL. Crohn’s disease of the esophagus. Curr Treat Options Gastroenterol. 2007;10:61–70.

    Article  Google Scholar 

  16. Heller T, James SP, Drachenberg C, Hernandez C, Darwin PE. Treatment of severe esophageal Crohn’s disease with infliximab. Inflamm. Bowel Dis.. 1999;5:279–282.

    Article  CAS  Google Scholar 

  17. Grassia R, Staiano T, Buffoli F, Paolo B. Severe esophageal Crohn’s disease: healing of lesions after 1 week therapy with infliximab. J Crohns Colitis. 2009;3:138–139.

    Article  Google Scholar 

  18. Barkin JA, Deshpande AR. Ustekinumab for successful treatment of refractory esophageal Crohn’s disease. ACG Case Rep J. 2016;3:107–108.

    Article  Google Scholar 

  19. Barkin JA, Schonfeld WB, Deshpande AR. Successful use of thalidomide for refractory esophageal Crohn’s disease. Am J Gastroenterol. 2013;108:855–857.

    Article  CAS  Google Scholar 

  20. Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2009;. https://doi.org/10.1002/14651858.cd007351.pub2.

    Article  PubMed  Google Scholar 

  21. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17:135–139.

    Article  CAS  Google Scholar 

  22. Feagans J, Victor D, Joshi V. Crohn disease of the esophagus: a review of the literature. South Med J. 2008;101:927–930.

    Article  Google Scholar 

  23. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550.e2–557.e2.

    Article  Google Scholar 

  24. Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45:933–940.

    Article  CAS  Google Scholar 

  25. El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn’s disease in children. Inflamm Bowel Dis. 2019;25:150–155.

    Article  Google Scholar 

  26. Adegbola SO, Sahnan K, Tozer PJ, et al. Review of local injection of anti-TNF for perianal fistulising Crohn’s disease. Int J Colorectal Dis. 2017;32:1539–1544.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Crohn’s and Colitis Center, Brigham and Women’s Hospital, Boston, MA, USA

    Alexander N. Levy & Matthew J. Hamilton

  2. Department of Radiology, Brigham and Women’s Hospital, Boston, MA, USA

    Naiim Ali

  3. Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

    Juliana Andrici

Authors
  1. Alexander N. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naiim Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juliana Andrici
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew J. Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew J. Hamilton.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Levy, A.N., Ali, N., Andrici, J. et al. It’s What’s Up Front That Counts—Part Two: Esophageal Crohn’s Disease Complicated by Recurrent Upper Gastrointestinal Bleeding. Dig Dis Sci 64, 3446–3450 (2019). https://doi.org/10.1007/s10620-019-05922-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05922-x

Search

Navigation